EE164 Cost-Effectiveness of Inclisiran as Add-on Therapy to Standard-of-Care for the Secondary Prevention of Cardiovascular Events in Patients with Elevated LDL Cholesterol
Dec 1, 2023, 00:00
10.1016/j.jval.2023.09.433
https://www.valueinhealthjournal.com/article/S1098-3015(23)03563-5/fulltext
Title :
EE164 Cost-Effectiveness of Inclisiran as Add-on Therapy to Standard-of-Care for the Secondary Prevention of Cardiovascular Events in Patients with Elevated LDL Cholesterol
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)03563-5&doi=10.1016/j.jval.2023.09.433
First page :
Section Title :
Open access? :
No
Section Order :
12460